Search research articles
Contact Us
Filters
Showing results (471-480 of 549) with videos related to
Page
of 55
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
May 11, 2021
Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients
Claudia C V Lang, Yael Renert-Yuval, Ester Del Duca, et al.
Plos One
|
May 24, 2013
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity
Franziska Ruëff, Bernhard Przybilla, Maria Beatrice Biló, et al.
NPJ Breast Cancer
|
June 26, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events
Hope S Rugo, David W Cescon, Peter Schmid, et al.
Cell Reports
|
March 1, 2018
PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer
Abbie E Fearon, Edward P Carter, Natasha S Clayton, et al.
The New England Journal of Medicine
|
January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Sara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
The Journal of Pathology. Clinical Research
|
April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119
Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Breast Cancer Research : BCR
|
January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Peter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
Page
of 55
Search research articles
Search
Showing results (471-480 of 549) with videos related to
Sort By:
Page
of 55
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
May 11, 2021
Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients
Claudia C V Lang, Yael Renert-Yuval, Ester Del Duca, et al.
Plos One
|
May 24, 2013
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity
Franziska Ruëff, Bernhard Przybilla, Maria Beatrice Biló, et al.
NPJ Breast Cancer
|
June 26, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events
Hope S Rugo, David W Cescon, Peter Schmid, et al.
Cell Reports
|
March 1, 2018
PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer
Abbie E Fearon, Edward P Carter, Natasha S Clayton, et al.
The New England Journal of Medicine
|
January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Sara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
The Journal of Pathology. Clinical Research
|
April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119
Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Breast Cancer Research : BCR
|
January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Peter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
Page
of 55